Cell Signaling Technology

Product Pathways - Development

TCF1 (C46C7) Rabbit mAb #2206

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP H M R Endogenous 28-50 Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

TCF1 (C46C7) Rabbit mAb detects endogenous levels of total TCF1 proteins. This antibody should detect all TCF1 isoforms, including those lacking the amino-terminal β-catenin binding domain. This antibody does not cross-react with LEF1.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to a region surrounding Leu158 of human TCF1 protein.

Western Blotting

Western Blotting

Western blot analysis of total cell lysates from HCT29, Colo201, Jurkat and mouse thymocytes using TCF1 (C46C7) Rabbit mAb.

Background

LEF1 and TCF are members of the high mobility group (HMG) DNA binding protein family of transcription factors that consists of the following: Lymphoid Enhancer Factor 1 (LEF1), T Cell Factor 1 (TCF1), TCF3, and TCF4 (1). LEF1 and TCF1 were originally identified as important factors regulating early lymphoid development (2) and act downstream in Wnt signaling. LEF1 and TCF bind to Wnt response elements to provide docking sites for β-catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1 and TCF are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers including colon cancer (4,5).

TCF1, also known as TCF7 (Transcription Factor 7), has several isoforms due to alternative splicing and transcription from an alternative promoter. The isoforms generated by the alternative promoter do not contain the amino-terminal β-catenin binding domain and therefore may function in a dominant negative manner (6). TCF1 displays dynamic expression both in the total amount and the type of isoforms expressed in T cells during development and differentiation (7).

  1. Waterman, M.L. (2004) Cancer Metastasis Rev. 23, 41-52.
  2. Schilham, M.W. and Clevers, H. (1998) Semin. Immunol. 10, 127-132.
  3. Brantjes, H. et al. (2002) Biol. Chem. 383, 255-261.
  4. Reya, T. and Clevers, H. (2005) Nature 434, 843-850.
  5. Logan, C.Y. and Nusse, R. (2004) Annu. Rev. Cell Dev. Biol. 20, 781-810.
  6. Waterman, M.L. Cancer Metastasis Rev. 23, 41-52.
  7. Willinger, T. et al. (2006) J. Immunol. 176, 1439-1446.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products